{"id":"https://openalex.org/W1986102787","doi":"https://doi.org/10.1007/s00213-014-3839-0","title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","display_name":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","publication_year":2015,"publication_date":"2015-01-09","ids":{"openalex":"https://openalex.org/W1986102787","doi":"https://doi.org/10.1007/s00213-014-3839-0","mag":"1986102787","pmid":"https://pubmed.ncbi.nlm.nih.gov/25575488","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4432084"},"language":"en","primary_location":{"id":"doi:10.1007/s00213-014-3839-0","doi":"https://doi.org/10.1007/s00213-014-3839-0","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00213-014-3839-0","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00213-014-3839-0.pdf","source":{"id":"https://openalex.org/S80334769","display_name":"Psychopharmacology","issn_l":"0033-3158","issn":["0033-3158","1432-2072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00213-014-3839-0.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112910391","display_name":"Atul R. Mahableshwarkar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]},{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP","US"],"is_corresponding":true,"raw_author_name":"Atul R. Mahableshwarkar","raw_affiliation_strings":["CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA, atul.mahableshwarkar@takeda.com","Takeda Development Center \u2013 Americas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA, atul.mahableshwarkar@takeda.com","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center \u2013 Americas","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024369212","display_name":"Paula L. Jacobsen","orcid":"https://orcid.org/0000-0003-0216-655X","observed_orcids":["https://orcid.org/0000-0003-0216-655X"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]},{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP","US"],"is_corresponding":false,"raw_author_name":"Paula L. Jacobsen","raw_affiliation_strings":["CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA","Takeda Development Center \u2013 Americas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center \u2013 Americas","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068791484","display_name":"Yinzhong Chen","orcid":"https://orcid.org/0009-0004-5224-4215","observed_orcids":["https://orcid.org/0009-0004-5224-4215"]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]},{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP","US"],"is_corresponding":false,"raw_author_name":"Yinzhong Chen","raw_affiliation_strings":["CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA","Takeda Development Center \u2013 Americas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center \u2013 Americas","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089404250","display_name":"Michael Serenko","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]},{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP","US"],"is_corresponding":false,"raw_author_name":"Michael Serenko","raw_affiliation_strings":["CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA","Takeda Development Center \u2013 Americas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CNS Medicine, Clinical Science, CNS Statistics, Pharmacovigilance, Takeda Development Center Americas, 1 Takeda Parkway, Deerfield, IL, 60015, USA","institution_ids":["https://openalex.org/I4210140176"]},{"raw_affiliation_string":"Takeda Development Center \u2013 Americas","institution_ids":["https://openalex.org/I44892455"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081426855","display_name":"Madhukar H. Trivedi","orcid":"https://orcid.org/0000-0002-2983-1110","observed_orcids":["https://orcid.org/0000-0002-2983-1110"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Madhukar H. Trivedi","raw_affiliation_strings":["Division of Mood Disorders, University of Texas Southwest Medical Center, Dallas, TX, USA","Division of Mood Disorders, University of Texas Southwest Medical Center, Dallas, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Mood Disorders, University of Texas Southwest Medical Center, Dallas, TX, USA","institution_ids":["https://openalex.org/I867280407"]},{"raw_affiliation_string":"Division of Mood Disorders, University of Texas Southwest Medical Center, Dallas, USA","institution_ids":["https://openalex.org/I867280407"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5112910391"],"corresponding_institution_ids":["https://openalex.org/I4210140176","https://openalex.org/I44892455"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":{"value":4390,"currency":"USD","value_usd":4390},"fwci":9.1369,"has_fulltext":true,"cited_by_count":101,"citation_normalized_percentile":{"value":0.98746125,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"232","issue":"12","first_page":"2061","last_page":"2070"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vortioxetine","display_name":"vortioxetine","score":1.0},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9929999709129333},{"id":"https://openalex.org/keywords/duloxetine","display_name":"duloxetine","score":0.8500000238418579},{"id":"https://openalex.org/keywords/acute-treatment","display_name":"acute treatment","score":0.5529999732971191},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.8859999775886536},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.746999979019165},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.6669999957084656},{"id":"https://openalex.org/keywords/sexual-dysfunction","display_name":"sexual dysfunction","score":0.7059999704360962},{"id":"https://openalex.org/keywords/suicidal-ideation","display_name":"suicidal ideation","score":0.9509999752044678},{"id":"https://openalex.org/keywords/discontinuation-symptoms","display_name":"discontinuation symptoms","score":0.7990000247955322},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6639999747276306}],"concepts":[{"id":"https://openalex.org/C2778034309","wikidata":"https://www.wikidata.org/wiki/Q3563148","display_name":"Vortioxetine","level":4,"score":0.9748226404190063},{"id":"https://openalex.org/C2780764818","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine","level":3,"score":0.8712315559387207},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7660983800888062},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.5490291118621826},{"id":"https://openalex.org/C2991744798","wikidata":"https://www.wikidata.org/wiki/Q608510","display_name":"Double blind","level":4,"score":0.53183913230896},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5139865279197693},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5033106207847595},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4163092374801636},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.410126268863678},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35988640785217285},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.31453990936279297},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.18886464834213257},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.1273326277732849},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068736","descriptor_name":"Duloxetine Hydrochloride","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000068736","descriptor_name":"Duloxetine Hydrochloride","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000078784","descriptor_name":"Vortioxetine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004562","descriptor_name":"Electrocardiography","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005221","descriptor_name":"Fatigue","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D005221","descriptor_name":"Fatigue","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007319","descriptor_name":"Sleep Initiation and Maintenance Disorders","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D007319","descriptor_name":"Sleep Initiation and Maintenance Disorders","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013440","descriptor_name":"Sulfides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013440","descriptor_name":"Sulfides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059020","descriptor_name":"Suicidal Ideation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1007/s00213-014-3839-0","doi":"https://doi.org/10.1007/s00213-014-3839-0","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00213-014-3839-0","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00213-014-3839-0.pdf","source":{"id":"https://openalex.org/S80334769","display_name":"Psychopharmacology","issn_l":"0033-3158","issn":["0033-3158","1432-2072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4432084","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4432084","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology (Berl)","raw_type":"Text"},{"id":"pmid:25575488","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25575488","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"Comparative Study"}],"best_oa_location":{"id":"doi:10.1007/s00213-014-3839-0","doi":"https://doi.org/10.1007/s00213-014-3839-0","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00213-014-3839-0","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00213-014-3839-0.pdf","source":{"id":"https://openalex.org/S80334769","display_name":"Psychopharmacology","issn_l":"0033-3158","issn":["0033-3158","1432-2072"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychopharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320310030","display_name":"Takeda Pharmaceuticals U.S.A.","ror":"https://ror.org/03bygaq51"},{"id":"https://openalex.org/F4320327918","display_name":"H. Lundbeck A/S","ror":"https://ror.org/0564cd633"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1986102787.pdf","grobid_xml":"https://content.openalex.org/works/W1986102787.grobid-xml"},"referenced_works_count":27,"referenced_works":["https://openalex.org/W845297282","https://openalex.org/W1970755410","https://openalex.org/W1976410377","https://openalex.org/W1983176528","https://openalex.org/W1987514922","https://openalex.org/W1987560991","https://openalex.org/W1993810702","https://openalex.org/W2001782289","https://openalex.org/W2011606125","https://openalex.org/W2029732660","https://openalex.org/W2036812642","https://openalex.org/W2048026164","https://openalex.org/W2054766240","https://openalex.org/W2057880023","https://openalex.org/W2058572593","https://openalex.org/W2059274457","https://openalex.org/W2061669920","https://openalex.org/W2066283885","https://openalex.org/W2089659183","https://openalex.org/W2131823335","https://openalex.org/W2132324173","https://openalex.org/W2137044513","https://openalex.org/W2148083007","https://openalex.org/W2149402043","https://openalex.org/W2159271064","https://openalex.org/W2160070901","https://openalex.org/W2164182651"],"related_works":["https://openalex.org/W2001782289","https://openalex.org/W810408096","https://openalex.org/W2752826413","https://openalex.org/W2054766240","https://openalex.org/W2061669920","https://openalex.org/W845297282","https://openalex.org/W2303297560","https://openalex.org/W4386888577","https://openalex.org/W4407057154","https://openalex.org/W2270496518"],"abstract_inverted_index":{"RATIONALE:":[0],"Vortioxetine":[1,198],"has":[2],"reduced":[3,202],"depressive":[4,10],"symptoms":[5,188],"in":[6,13,39,69,118],"adults":[7,40],"with":[8,41],"major":[9],"disorder":[11],"(MDD)":[12],"multiple":[14],"clinical":[15],"trials.":[16],"OBJECTIVES:":[17],"The":[18,62],"aim":[19],"of":[20,31,161,209],"this":[21],"study":[22],"is":[23],"to":[24,48],"evaluate":[25],"the":[26],"efficacy,":[27],"safety,":[28],"and":[29,34,102,105,111,128,145,175,186,195],"tolerability":[30],"vortioxetine":[32,49,52,133,139,162,194,212],"15":[33,50,134],"20":[35,53,140,199],"mg":[36,57,135,141,148,200],"vs":[37,153],"placebo":[38],"MDD.":[42],"METHODS:":[43],"Patients":[44],"were":[45,114,121,189,214],"randomized":[46],"1:1:1:1":[47],"mg,":[51,54],"duloxetine":[55,146],"60":[56,147],"(active":[58],"reference),":[59],"or":[60,184],"placebo.":[61,196],"primary":[63],"efficacy":[64],"endpoint":[65],"was":[66],"mean":[67],"change":[68],"Montgomery-\u00c5sberg":[70],"Depression":[71],"Rating":[72,96],"Scale":[73],"(MADRS)":[74],"total":[75,204],"score":[76],"at":[77],"week":[78],"8":[79,207],"(MMRM).":[80],"Safety/tolerability":[81],"assessments":[82],"included":[83,164],"physical":[84],"examinations,":[85],"vital":[86],"signs,":[87],"laboratory":[88],"evaluations,":[89],"electrocardiograms,":[90],"adverse":[91],"events":[92],"(AEs),":[93],"Columbia-Suicide":[94],"Severity":[95],"Scale,":[97,101],"Arizona":[98],"Sexual":[99],"Experiences":[100],"Discontinuation-Emergent":[103],"Signs":[104],"Symptoms":[106],"checklist.":[107],"RESULTS:":[108],"Six":[109],"hundred":[110],"fourteen":[112],"patients":[113,163],"randomized.":[115],"Mean":[116],"changes":[117],"MADRS":[119,203],"scores":[120,205],"-12.83":[122],"(\u00b10.834),":[123],"-14.30":[124],"(\u00b10.890),":[125],"-15.57":[126],"(\u00b10.880),":[127],"-16.90":[129],"(\u00b10.884)":[130],"for":[131],"placebo,":[132],"(P":[136,142,149,152],"=":[137,143],".224),":[138],".023),":[144],"<":[150],".001)":[151],"placebo),":[154],"respectively.":[155],"AEs":[156],"reported":[157],"by":[158],"\u22655":[159],"%":[160],"nausea,":[165],"headache,":[166],"diarrhea,":[167],"dizziness,":[168],"dry":[169],"mouth,":[170],"constipation,":[171],"vomiting,":[172],"insomnia,":[173],"fatigue,":[174],"upper":[176],"respiratory":[177],"infection.":[178],"Treatment-emergent":[179],"sexual":[180],"dysfunction,":[181],"suicidal":[182],"ideation":[183],"behavior,":[185],"discontinuation":[187],"not":[190],"significantly":[191,201],"different":[192],"between":[193],"CONCLUSIONS:":[197],"after":[206],"weeks":[208],"treatment.":[210],"Both":[211],"doses":[213],"well":[215],"tolerated.":[216],"CLINICAL":[217],"TRIAL":[218],"REGISTRATION:":[219],"ClinicalTrials.gov":[220],"identifier":[221],"NCT01153009;":[222],"www.clinicaltrials.gov/":[223],".":[224]},"counts_by_year":[{"year":2025,"cited_by_count":12},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":10},{"year":2015,"cited_by_count":11}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}